GLP1R and cancer: It is clear that more preclinical research examining potential protumorigenic effects of GLP-1RAs and related incretin mimetics (e.g., tirzepatide) on GLP-1R-positive NETs, particularly dNETs and pNETs, is needed to better understand the safety of these drugs in NEN patients or other GLP-1R-expressing cancers (12, 13).